Skip to main content

Table 2 TRK inhibitors currently in clinical development

From: Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers

Drug name

Targets

Development stage

Clinical trial identifier

Company

LOXO-101 (larotrectinib)

NTRK1/2/3

Phase II

NCT02122913

NCT02637687

NCT02576431

NCT03213704

Loxo Oncology

LOXO-195

NTRK1/2/3 (resistant)

Phase I/II

NCT03215511

Loxo Oncology

RXDX-101 (entrectinib)

NTRK1/2/3, ALK, ROS1

Phase I/II,

Phase II,

Phase I/Ib

NCT02097810

NCT02568267

NCT02650401

Ignyta

TPX-0005 (ropotrectinib)

NTRK1/2/3, ALK, ROS1 (resistant), JAK2, SRC, DDR1, FAK

Phase I/II

NCT03093116

TP Therapeutics

LY2801653 (merestinib)

NTRK1/2/3, MET, MST1R, FLT3, AXL, MERTK, TEK, ROS1, DDR1/2, MKNK1/2

Phase II

NCT02920996

Eli Lilly and Company

DS-6051b

NTRK1/2/3, ROS1

Phase I

NCT02675491

NCT02279433

Daiichi Sankyo

PLX7486

NTRK1/2/3, CSF1R

Phase I

NCT01804530

Plexxikon/Daiichi Sankyo

MGCD516 (sitravatinib)

NTRK1/2/3, MET, KIT, PDGFRA, KDR, DDR2, RET, CBL

Phase I/Ib

NCT02219711

Mirati Therapeutics